Compare Aurora Cannabis Inc (ACB) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

USIG trades at $51.09 with no change in the last session. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent news highlights a significant 63.4% increase in short interest as of April 15, 2026 (Defense World), and Fifth Third Securities reduced its stake by 54.7% in the latest quarter (Defense World, 2026-04-13). The ETF maintains regular dividend distributions, with the most recent being $0.20 paid on July 7, 2026.

The outlook for USIG is cautious due to bearish technical signals and rising short interest. Investment opportunities include steady dividend income, but risks involve potential price pressure from increased short selling and institutional selling. Investors should weigh the ETF's fixed-income characteristics against current market sentiment and technical weakness.